CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
三类暴露复发/难治性多发性骨髓瘤患者的特征、治疗模式与结局：基于捷克登记数据的回顾性观察性研究
英文原题：Patient Characteristics, Treatment Patterns, and Outcomes in Triple-Class Exposed Relapsed/Refractory Multiple Myeloma Patients, a Retrospective Observational Study Using Czech Registry Data.
查看英文原题
Patient Characteristics, Treatment Patterns, and Outcomes in Triple-Class Exposed Relapsed/Refractory Multiple Myeloma Patients, a Retrospective Observational Study Using Czech Registry Data.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
研究概要
与来自美国和欧洲的先前研究相似，我们的结果显示出较高的疾病负担。引入新型疗法，如 CAR-T 细胞、新的双特异性和三特异性单克隆抗体以及其他药物，预计将为这些患者带来显著获益。
研究思路结论见上方概要
背景
尽管新型疗法改善了多发性骨髓瘤（MM）患者的预后，但多重难治人群的临床结局仍然不佳。
方法
我们回顾了捷克单克隆丙种球蛋白病登记处的数据，识别并描述了三类暴露（3CE）的复发/难治性MM患者，分析了3CE后的治疗模式，评估了总生存期（OS）、无进展生存期（PFS）、至下次治疗时间（TTNT），并探索了三重和五重难治性及非难治性队列。
结果
在83例开始后续治疗的3CE患者中，中位OS为14.2个月（95% CI，8.5-19.9），PFS为6.2个月（95% CI，3.9-8.5），TTNT为7.2个月（95% CI，4.6-9.8）。三药难治和五药难治患者在所有结局中预后均显著更差。其预期寿命更短，疾病进展更早，TTNT更短，这增加了对更多治疗产生难治的可能性。从首次索引日期和所有索引日期分析获得的时间-事件结果非常相似。
展开英文摘要原文
BACKGROUND
Although novel therapies improved prognosis of multiple myeloma (MM) patients, clinical outcomes in the multi-refractory population are still poor.
PATIENTS AND METHODS
We reviewed data from the Czech Registry of Monoclonal Gammopathies, identified and characterized triple-class exposed (3CE) relapsed/refractory MM patients, treatment patterns after 3CE, assessed overall survival (OS), progression-free survival (PFS), time to next treatment (TTNT), explored cohorts with and without triple- and penta-refractoriness.
RESULTS
In 83 3CE patients who started subsequent therapies, the median OS was 14.2 months (95% CI, 8.5-19.9), PFS 6.2 months (95% CI, 3.9-8.5), and TTNT 7.2 months (95% CI, 4.6-9.8). Triple- and penta-class refractory patients had a significantly worse prognosis in all outcomes. Their life expectancy was shorter, the disease progression started earlier, and the TTNT was shorter, which increased likelihood of becoming refractory to more therapies. Time-to-event results from the first index date and all index dates analyses were very similar.
CONCLUSION
Similar to previous studies from the US and Europe, our results show a high disease burden. Introduction of novel therapies, such as CAR-T cells, new bispecific and trispecific monoclonal antibodies, and other drugs, is expected to bring significant benefits to these patients.
论文信息
- 作者
- Maisnar V、Pour L、Spicka I、Jelinek T、Minarik J、Jungova A、Stork M、Straub J
- 第一作者单位
- Fourth Department of Internal Medicine - Hematology, University Hospital and Faculty of Medicine Hradec Kralove, Charles University, Hradec Kralove, Czech Republic.Czechia
- 通讯作者单位
- Department of Hemato-Oncology, University Hospital Ostrava and Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic. Electronic address: roman.hajek@fno.cz.Czechia
- 文献类型
- 观察性研究 · 非美国政府资助研究
- 期刊
- Clinical lymphoma, myeloma & leukemia2023 Feb
- 原文标识
- PubMed 36567210 · DOI 10.1016/j.clml.2022.11.001